Microarray analysis of gene expression of cancer to guide the use of chemotherapeutics

Taiwanese Journal of Obstetrics and Gynecology

Volumn 46, Issue 3, 2007, Pages 222-229

  Wang, Tzu Hao ^a   Chao, Angel ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cancer therapeutics; Clinical application; Gene expression; Genomic signatures; Microarrays

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; B CELL LYMPHOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CORRELATION FUNCTION; DATA ANALYSIS; EMERGENCY HEALTH SERVICE; GENE; GENE EXPRESSION; HUMAN; INFORMATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; OVARY CANCER; PATHOLOGY; PHYSIOLOGY; PREDICTION; PREDICTOR VARIABLE; REVIEW; SOLID TUMOR; TUMOR GENE; UTERINE CERVIX CANCER; VALIDATION STUDY;

EID: 35348860246     PISSN: 10284559     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1028-4559(08)60024-8     Document Type: Review

References (60)

1. Wang TH, Lee YS, Chen ES, et al. Establishment of cDNA microarray analysis at the Genomic Medicine Research Core Laboratory (GMRCL) of Chang Gung Memorial Hospital. Chang Gung Med J 2004;27:243-60.
2. Chao A, Wang TH, Lai CH. Overview of microarray analysis of gene expression and its applications to cervical cancer investigation. Taiwan J Obstet Gynecol 2007 (In press).
3. Lee YS, Chen CH, Chao A, et al. Molecular signature of clinical severity in recovering patients with severe acute respiratory syndrome Coronavirus (SARS-CoV). BMC Genomics 2005;6:132.
4. Chao A, Wang TH, Lee YS, et al. Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. Int J Cancer 2006;119:91-8.
5. Wang TH, Chan YH, Chen CW, et al. Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways. Oncogene 2006;25:4857-66.
6. Tsai MS, Hwang SM, Chen KD, et al. Functional network analysis on the transcriptomes of mesenchymal stem cells derived from amniotic fluid, amniotic membrane, cord blood, and bone marrow. Stem Cells 2007 (In press).
7. Tan PK, Downey TJ, Spitznagel EL Jr, et al. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res 2003;31:5676-84.
8. Yauk CL, Berndt ML, Williams A, Douglas GR. Comprehensive comparison of six microarray technologies. Nucleic Acids Res 2004;32:e124.
9. Carter SL, Eklund AC, Mecham BH, Kohane IS, Szallasi Z. Redefinition of Affymetrix probe sets by sequence overlap with cDNA microarray probes reduces cross-platform inconsistencies in cancer-associated gene expression measurements. BMC Bioinformatics 2005;6:107.
10. Wang H, He X, Band M, Wilson C, Liu L. A study of interlab and inter-platform agreement of DNA microarray data. BMC Genomics 2005;6:71.
11. Fortunel NO, Otu HH, Ng HH, et al. Comment on "'Stemness': transcriptional profiling of embryonic and adult stem cells" and "a stem cell molecular signature". Science 2003;302:393; author reply 393.
12. Marshall E. Getting the noise out of gene arrays. Science 2004;306:630-1.
13. Strauss E. Arrays of hope. Cell 2006;127:657-9.
14. Tong W, Lucas AB, Shippy R, et al. Evaluation of external RNA controls for the assessment of microarray performance. Nat Biotechnol 2006;24:1132-9.
15. Canales RD, Luo Y, Willey JC, et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 2006;24:1115-22.
16. Patterson TA, Lobenhofer EK, Fulmer-Smentek SB, et al. Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol 2006;24:1140-50.
17. Shi L, Reid LH, Jones WD, et al, for MAQC Consortium. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006;24:1151-61.
18. Guo L, Lobenhofer EK, Wang C, et al. Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat Biotechnol 2006;24:1162-9.
19. Liu ET, Karuturi KR. Microarrays and clinical investigations. N Engl J Med 2004;350:1595-7.
20. Grimwade D, Haferlach T. Gene-expression profiling in acute myeloid leukemia. N Engl J Med 2004;350:1676-8.
21. Febbo PG, Kantoff PW. Noise and bias in microarray analysis of tumor specimens. J Clin Oncol 2006;24:3719-21.
22. Rhodes DR, Chinnaiyan AM. Integrative analysis of the cancer transcriptome. Nat Genet 2005;37(Suppl):S31-7.
23. Segal E, Friedman N, Kaminski N, Regev A, Koller D. From signatures to models: understanding cancer using microarrays. Nat Genet 2005;37(Suppl):S38-45.
24. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-8.
25. Rhodes DR, Yu J, Shanker K, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 2004;101:9309-14.
26. Harris MA, Clark J, Ireland A, et al, for Gene Ontology Consortium. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 2004;32(Database issue):D258-61.
27. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM. Mining for regulatory programs in the cancer transcriptome. Nat Genet 2005;37:579-83.
28. Weinmann AS, Yan PS, Oberley MJ, Huang TH, Farnham PJ. Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. Genes Dev 2002;16:235-44.
29. Odom DT, Zizlsperger N, Gordon DB, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science 2004;303:1378-81.
30. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1 alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003;34:267-73.
31. Segal E, Friedman N, Koller D, Regev A. A module map showing conditional activity of expression modules in cancer. Nat Genet 2004;36:1090-8.
32. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
33. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
34. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
35. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
36. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
37. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
38. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-300.
39. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350:1828-37.
40. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999;96:9212-7.
41. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18.
42. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-42.
43. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-67.
44. Liotta LA, Kohn EC. Cancer's deadly signature. Nat Genet 2003;33:10-1.
45. Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004;350:1605-16.
46. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004;350:1617-28.
47. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005;365:488-92.
48. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
49. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
50. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005;102:3738-43.
51. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004;2:E7.
52. Rosenwald A, Wright G, Chan WC, et al, for the Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
53. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-9.
54. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
55. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001;19:1734-42.
56. Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 2001;98:10787-92.
57. Gyorffy B, Surowiak P, Kiesslich O, Denken C, Schafer R, Dietel M, Lage H. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 2006;118:1699-712.
58. Herbst RS, Lippman SM. Molecular signatures of lung cancer-toward personalized therapy. N Engl J Med 2007;356:76-8.
59. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80.
60. Dressman HK, Berchuck A, Chan G, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25:517-25.